SG10201605324PA - Lyophilized preparation of botulinum toxin - Google Patents

Lyophilized preparation of botulinum toxin

Info

Publication number
SG10201605324PA
SG10201605324PA SG10201605324PA SG10201605324PA SG10201605324PA SG 10201605324P A SG10201605324P A SG 10201605324PA SG 10201605324P A SG10201605324P A SG 10201605324PA SG 10201605324P A SG10201605324P A SG 10201605324PA SG 10201605324P A SG10201605324P A SG 10201605324PA
Authority
SG
Singapore
Prior art keywords
botulinum toxin
lyophilized preparation
lyophilized
preparation
botulinum
Prior art date
Application number
SG10201605324PA
Inventor
Hyun Ho Jung
Gi Hyeok Yang
Chang Hoon Rhee
Hack Woo Kim
Sung Bum Kim
Seung Hwan Baek
Original Assignee
Medy Tox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47282510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201605324P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medy Tox Inc filed Critical Medy Tox Inc
Publication of SG10201605324PA publication Critical patent/SG10201605324PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG10201605324PA 2011-03-31 2012-03-30 Lyophilized preparation of botulinum toxin SG10201605324PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110029577 2011-03-31
KR1020120033374A KR101395064B1 (en) 2011-03-31 2012-03-30 Lyophilized Preparation of Botulinun Toxin

Publications (1)

Publication Number Publication Date
SG10201605324PA true SG10201605324PA (en) 2016-08-30

Family

ID=47282510

Family Applications (3)

Application Number Title Priority Date Filing Date
SG2013073622A SG194039A1 (en) 2011-03-31 2012-03-30 Lyophilized preparation of botulinum toxin
SG10201605324PA SG10201605324PA (en) 2011-03-31 2012-03-30 Lyophilized preparation of botulinum toxin
SG10202013124XA SG10202013124XA (en) 2011-03-31 2012-03-30 Lyophilized preparation of botulinum toxin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013073622A SG194039A1 (en) 2011-03-31 2012-03-30 Lyophilized preparation of botulinum toxin

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202013124XA SG10202013124XA (en) 2011-03-31 2012-03-30 Lyophilized preparation of botulinum toxin

Country Status (22)

Country Link
US (3) US8920795B2 (en)
EP (3) EP3756656A1 (en)
JP (3) JP5826914B2 (en)
KR (1) KR101395064B1 (en)
CN (2) CN109925284A (en)
AU (2) AU2012233845B2 (en)
BR (1) BR112013025256B1 (en)
CA (1) CA2831908C (en)
CO (1) CO6821888A2 (en)
DK (2) DK2692350T4 (en)
ES (2) ES2636680T5 (en)
HK (1) HK1246174A1 (en)
HU (1) HUE050037T2 (en)
IL (1) IL228607B (en)
MX (2) MX338436B (en)
PL (2) PL2692350T5 (en)
PT (1) PT3241547T (en)
RU (2) RU2640922C1 (en)
SG (3) SG194039A1 (en)
SI (1) SI3241547T1 (en)
WO (1) WO2012134240A2 (en)
ZA (1) ZA201308115B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100852824B1 (en) * 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 Therapeutic composition with a botulinum neurotoxin
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
KR101087017B1 (en) * 2007-07-10 2011-12-09 (주)메디톡스 Stable liquid composition of Botulinum Toxin
HUE037595T2 (en) 2008-12-31 2018-09-28 Revance Therapeutics Inc Injectable botulinum toxin formulations
MX344583B (en) 2009-06-25 2016-12-20 Revance Therapeutics Inc Albumin-free botulinum toxin formulations.
RU2640922C1 (en) * 2011-03-31 2018-01-12 Меди-Токс Инк. Lyophilised preparation of botulinum toxin
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
JP6643324B2 (en) 2014-09-02 2020-02-12 アメリカン シルヴァー リミテッド ライアビリティ カンパニー Botulinum toxin and colloidal silver particles
WO2016080367A1 (en) * 2014-11-18 2016-05-26 塩野義製薬株式会社 Stable peptide composition
KR101737387B1 (en) 2015-06-01 2017-05-18 유용우 Manufacturing method of health food using the ginseng by double fermented
CN108463242A (en) * 2016-03-02 2018-08-28 梅尔兹制药公司 Include the composition of botulin toxin
US10369190B2 (en) * 2016-09-13 2019-08-06 Allergan, Inc. Non-protein clostridial toxin compositions
KR101744900B1 (en) 2017-01-20 2017-06-08 주식회사 대웅 Stable Liquid Composition Comprising Botulinum Toxin
CN107540732B (en) * 2017-08-31 2020-07-14 青海省畜牧兽医科学院 Biomimetic mineralization processing method and application of D-type botulinum toxin
KR101968873B1 (en) * 2018-09-21 2019-04-29 아이큐어 주식회사 Cosmetic composition comprising peptide derived from Botulinum toxin having improved cell penetrating ability
KR102259423B1 (en) * 2018-11-30 2021-06-02 주식회사 휴온스바이오파마 The composition for stability of Botulinum Toxin
WO2020111852A1 (en) * 2018-11-30 2020-06-04 주식회사 휴온스글로벌 Botulinum toxin-stabilizing liquid composition
SG11202107565RA (en) 2019-02-21 2021-08-30 Merz Pharma Gmbh & Co Kgaa Novel uses of botulinum neurotoxin for the treatment of tremor
CN110637814B (en) * 2019-10-22 2021-11-19 青海省畜牧兽医科学院 Method for preparing D-type botulinum toxin through microencapsulation
EP4052753A4 (en) * 2019-10-31 2023-11-15 Hugel Inc. Microstructure formulation technique for botulinum toxin
US20230256064A1 (en) 2020-07-23 2023-08-17 Medytox Inc. Cancer therapeutic agent
KR102414997B1 (en) * 2020-09-29 2022-06-29 주식회사 엘지생활건강 Composition comprising recombinant botulinum toxin light chain protein having improved stability
KR20220114183A (en) * 2021-02-08 2022-08-17 주식회사 대웅 Botulinum toxin freeze-dried formulation for long-term storage
KR20230001254A (en) 2021-06-28 2023-01-04 (주)메디톡스 Recombinant botulinum toxin type A light chain, recombinant botulinum toxin, and its compositions, uses and methods
KR20230001260A (en) 2021-06-28 2023-01-04 (주)메디톡스 Recombinant botulinum toxin type A light chain, recombinant botulinum toxin, and its compositions, uses and methods
KR102427362B1 (en) 2021-11-11 2022-08-01 (주)이니바이오 Drying system for Botulinum toxin formulation
KR20230071072A (en) * 2021-11-15 2023-05-23 (주)메디톡스 Botulinum toxin composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
BR0108173A (en) 2000-02-08 2003-01-21 Allergan Inc Botulinum toxin pharmaceutical compositions
DE10333317A1 (en) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulation for protein medicines without the addition of human serum albumin (HSA)
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
CN101175478A (en) * 2005-10-06 2008-05-07 阿勒根公司 Non-protein stabilized clostridial toxin pharmaceutical compositions
WO2008145359A1 (en) * 2007-06-01 2008-12-04 Merz Pharma Gmbh & Co. Kgaa Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
KR101087017B1 (en) * 2007-07-10 2011-12-09 (주)메디톡스 Stable liquid composition of Botulinum Toxin
KR20110106346A (en) * 2008-12-10 2011-09-28 알러간, 인코포레이티드 Clostridial toxin pharmaceutical compositions
KR101135449B1 (en) * 2009-03-10 2012-04-13 한국과학기술연구원 Ionic Complex Nanoparticle for Detecting Heparanase Activity and Method for Preparing the Same
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
RU2640922C1 (en) * 2011-03-31 2018-01-12 Меди-Токс Инк. Lyophilised preparation of botulinum toxin
US20130236446A1 (en) * 2012-03-12 2013-09-12 William J. Binder Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the mouth

Also Published As

Publication number Publication date
WO2012134240A3 (en) 2013-01-03
RU2640922C1 (en) 2018-01-12
EP2692350A4 (en) 2014-12-10
MX338436B (en) 2016-04-18
JP6005239B2 (en) 2016-10-12
CN103596580A (en) 2014-02-19
WO2012134240A2 (en) 2012-10-04
DK2692350T3 (en) 2017-08-21
SG10202013124XA (en) 2021-02-25
US8920795B2 (en) 2014-12-30
MX2013011119A (en) 2014-02-27
EP3241547B1 (en) 2020-05-20
US20160089442A1 (en) 2016-03-31
DK3241547T3 (en) 2020-08-17
JP5826914B2 (en) 2015-12-02
EP3241547A1 (en) 2017-11-08
JP2016020382A (en) 2016-02-04
BR112013025256B1 (en) 2022-01-18
AU2012233845A1 (en) 2013-10-31
AU2012233845B2 (en) 2015-11-19
IL228607B (en) 2018-10-31
ZA201308115B (en) 2014-07-30
EP2692350B1 (en) 2017-05-03
EP2692350B2 (en) 2023-06-28
SI3241547T1 (en) 2020-10-30
SG194039A1 (en) 2013-11-29
JP6173547B2 (en) 2017-08-02
DK2692350T4 (en) 2023-09-04
KR101395064B1 (en) 2014-05-19
ES2810098T3 (en) 2021-03-08
MX355771B (en) 2018-04-30
HK1246174A1 (en) 2018-09-07
KR20120112248A (en) 2012-10-11
US20140086900A1 (en) 2014-03-27
PL3241547T3 (en) 2021-02-08
BR112013025256A2 (en) 2017-02-07
RU2574011C2 (en) 2016-01-27
CA2831908A1 (en) 2012-10-04
PL2692350T5 (en) 2023-10-09
EP2692350A2 (en) 2014-02-05
PL2692350T3 (en) 2017-10-31
ES2636680T3 (en) 2017-10-06
IL228607A0 (en) 2013-12-31
CO6821888A2 (en) 2013-12-31
PT3241547T (en) 2020-08-26
EP3756656A1 (en) 2020-12-30
US20150064166A1 (en) 2015-03-05
AU2016201040A1 (en) 2016-03-10
CA2831908C (en) 2018-11-13
ES2636680T5 (en) 2023-10-31
RU2013148119A (en) 2015-05-27
JP2016199599A (en) 2016-12-01
JP2014509644A (en) 2014-04-21
US9198958B2 (en) 2015-12-01
HUE050037T2 (en) 2020-11-30
AU2016201040B2 (en) 2017-05-25
CN109925284A (en) 2019-06-25

Similar Documents

Publication Publication Date Title
HK1246174A1 (en) Lyophilized preparation of botulinum toxin
HUS1900047I1 (en) Lyophilized liposomes
ZA201306118B (en) Lyophilized formulations
HK1216501A1 (en) Lyophilized preparations of melphalan flufenamide
HK1215793A1 (en) Lyophilized formulation of tat-nr2b9c tat-nr2b9c
ZA201308698B (en) Freeze-dried formulations of fgf-18
HK1250492A1 (en) Lyophilized preparation of cytotoxic dipeptides
ZA201503635B (en) Lyophilized preparations of melphalan flufenamide
GB201120078D0 (en) Variant toxin
HK1250654A1 (en) Freeze-dried formulations of fgf-18
EP2834268A4 (en) Modified peptide toxins
GB201111924D0 (en) Detection of clostridium